Inquiry

Rare Allergic Diseases Diagnostics Development Services

Diagnosing rare allergic diseases presents unique challenges due to their low prevalence and diverse symptoms. Protheragen offers comprehensive services as medical science and innovative technologies advance. Our diagnostic development services are designed to provide rapid and accurate strategies to identify and detect rare allergic diseases.

Introduction to Rare Allergic Diseases

Rare allergic diseases belong to the category of rare diseases which affect 5-8% of people worldwide with 80% of these disorders being genetically derived. European Union criteria classify a disease as rare when its occurrence falls below one in 2000 people. The current number of identified rare diseases stands between 6000 and 8000 but continues to grow annually with the discovery of new diseases. The development of diagnostics for rare allergic diseases requires multidisciplinary collaboration alongside technological advances and strong policy frameworks. The procedure combines state-of-the-art molecular diagnostic technologies with artificial intelligence and fast diagnostic instruments to enhance both precision and operational speed.

Our Services

Protheragen remains fully committed to developing diagnostic solutions for rare allergic diseases while delivering advanced and complete diagnostic services. Our team possesses extensive knowledge of contemporary technologies and methods which guarantees precise and prompt development of diagnostic solutions. We provide specialized services that utilize advanced molecular diagnostics alongside artificial intelligence and rapid assessment tools to solve research and diagnosis problems in rare allergic conditions for better clinical results and deeper disease understanding.

Diagnostics Development Platforms

Our Advantages

Leveraging our extensive experience in the field of rare allergic disease diagnostics, Protheragen offers robust support to ensure quick adaptation to emerging research demands. We deliver expert consultation and assistance, encompassing everything from the development of cutting-edge diagnostic tools to innovative analysis techniques. For further details and to request a quotation, please reach out to us.

Reference

• Giulia D, et al. Applications of basophil activation test in paediatric allergic diseases. World Allergy Organ J. 2024 Dec 9;17(12):100998.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Urticaria
• Non-Histaminic Angioedemaema
• Rare Allergic Respiratory Diseases
• Severe Dermatitis-Multiple Allergies-Metabolic Wasting Syndrome
• Rare Allergic Diseases Therapeutics Development Services
• Rare Allergic Diseases Drug Repurposing Service
• Rare Allergic Diseases Model Development Services
• Rare Allergic Diseases Drug Safety Evaluation Services
• Rare Allergic Diseases Pharmacokinetics Services
• Rare Allergic Diseases Small Molecule Drug Development Platforms
• Rare Allergic Diseases Cell Therapy Development Platforms
• Rare Allergic Diseases Gene Therapy Development Platforms
• Rare Allergic Diseases Therapeutic Antibody Development Platforms
• Rare Allergic Diseases Therapeutic Peptide Development Platform
• Rare Allergic Diseases Therapeutic Protein Development Platform